
Fibrobiologics Inc (FBLG) Stock Forecast & Price Target
Fibrobiologics Inc (FBLG) Analyst Ratings
Bulls say
FibroBiologics is a promising clinical-stage biotechnology company with a diverse pipeline that includes CYWC628, CYPS317, CYMS101, and CybroCell for various chronic diseases with high unmet medical needs, such as diabetic foot ulcers, multiple sclerosis, psoriasis, and degenerative disc disease. The upcoming proof-of-concept interim clinical results for CYWC628 in diabetic foot ulcer patients are expected to be the key factor that will drive appreciation for the potential of the broader fibroblast therapy pipeline. The company's deep IP moat, versatile platform across indications, and scalability potential make it a strong candidate for success in the biotech space.
Bears say
FibroBiologics is facing a number of challenges in the biotech industry, including regaining compliance with Nasdaq's listing requirements, a recent dilutive public offering, and the need for validation of their fibroblast therapy in patients with diabetic foot ulcers (DFU) in the first half of 2026. With a conservative estimate of 8% market penetration and the potential for complications in their stem cell-based therapy, the future success of FibroBiologics remains uncertain, leading to a negative outlook on the company's stock. Further financial data indicates that their burn care program is a potential growth opportunity, but with a highly competitive market and challenges in achieving regulatory approval for their novel delivery system, it may not be enough to significantly impact their overall financials.
This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.
Fibrobiologics Inc (FBLG) Analyst Forecast & Price Prediction
Start investing in Fibrobiologics Inc (FBLG)
Order type
Buy in
Order amount
Est. shares
0 shares